Carles Gaig1, Yaroslau Compta2. 1. Multidisciplinary Sleep Unit. 2. Parkinson's Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Institut de Neurociències Centro de Investigación Biomedica en Red Enfermedades Neurodegenerativas (CIBERNED).
Abstract
PURPOSE OF REVIEW: Anti-IgLON5 disease is a novel entity characterized by a distinctive sleep disorder associated with a variety of neurological symptoms, antibodies against IgLON5, and pathological findings of neuronal tauopathy. The characteristic sleep disorder occurs in most patients, but other neurological symptoms are also important because they can be the presenting and most disabling problem and mimic other conditions. This review focuses on nonsleep neurological symptoms and presentations of anti-IgLON5 disease. RECENT FINDINGS: Apart from sleep problems, the most frequent neurological symptoms in anti-IgLON5 disease are bulbar dysfunction and gait abnormalities. Other symptoms include movement disorders like chorea or abnormal orofacial movements, oculomotor abnormalities, cognitive impairment, and symptoms of nervous system hyperexcitability. All these symptoms can present in different combinations and severity leading to distinct clinical phenotypes beyond the sleep disorder: bulbar syndrome; syndrome resembling progressive supranuclear palsy; cognitive impairment, sometimes with chorea, mimicking Huntington disease; gait ataxia; and stiff-person-like syndrome. SUMMARY: These clinical presentations may suggest degenerative or other neurological disorders, but anti-IgLON5 disease has to be considered, and confirmed by the detection of IgLON5 antibodies, when the criteria for the diagnosis of the initially suspected disorders are not fulfilled, confirmatory laboratory tests are negative, and significant sleep problems are present.
PURPOSE OF REVIEW: Anti-IgLON5 disease is a novel entity characterized by a distinctive sleep disorder associated with a variety of neurological symptoms, antibodies against IgLON5, and pathological findings of neuronal tauopathy. The characteristic sleep disorder occurs in most patients, but other neurological symptoms are also important because they can be the presenting and most disabling problem and mimic other conditions. This review focuses on nonsleep neurological symptoms and presentations of anti-IgLON5 disease. RECENT FINDINGS: Apart from sleep problems, the most frequent neurological symptoms in anti-IgLON5 disease are bulbar dysfunction and gait abnormalities. Other symptoms include movement disorders like chorea or abnormal orofacial movements, oculomotor abnormalities, cognitive impairment, and symptoms of nervous system hyperexcitability. All these symptoms can present in different combinations and severity leading to distinct clinical phenotypes beyond the sleep disorder: bulbar syndrome; syndrome resembling progressive supranuclear palsy; cognitive impairment, sometimes with chorea, mimicking Huntington disease; gait ataxia; and stiff-person-like syndrome. SUMMARY: These clinical presentations may suggest degenerative or other neurological disorders, but anti-IgLON5 disease has to be considered, and confirmed by the detection of IgLON5 antibodies, when the criteria for the diagnosis of the initially suspected disorders are not fulfilled, confirmatory laboratory tests are negative, and significant sleep problems are present.
Authors: Sri Raghav Sista; Brian Crum; Albert Aboseif; Michelle F Devine; Anastasia Zekeridou; M Bakri Hammami; Mohammed M Rezk; André Truffert; Patrice H Lalive; Amy Kunchok; Andrew McKeon; Divyanshu Dubey Journal: J Neurol Date: 2022-07-20 Impact factor: 6.682
Authors: Carles Gaig; Yaroslau Compta; Anna Heidbreder; Maria J Marti; Maarten J Titulaer; Yvette Crijnen; Birgit Högl; Jan Lewerenz; María Elena Erro; Juan Carlos Garcia-Monco; Pasquale Nigro; Nicola Tambasco; Maja Patalong-Ogiewa; Marcus Erdler; Stefan Macher; Evelyn Berger-Sieczkowski; Romana Höftberger; Christian Geis; Markus Hutterer; Angela Milán-Tomás; Antonio Martin-Bastida; Lydia Lopez Manzanares; Sonia Quintas; Günter U Höglinger; Nora Möhn; Florian Schoeberl; Franziska S Thaler; Gian Maria Asioli; Federica Provini; Giuseppe Plazzi; Koldo Berganzo; Morten Blaabjerg; Norbert Brüggemann; Tarsis Farias; Chen Fei Ng; Caroline Giordana; Alejandro Herrero-San Martín; Lucio Huebra; Katya Kotschet; Herburg Liendl; Teresa Montojo; Carlos Morata; Jesus Perez Perez; Inmaculada Puertas; Thomas Seifert-Held; Caspar Seitz; Mateus Mistieri Simabukuro; Nieves Tellez; Javier Villacieros-Álvarez; Barbara Willekens; Lidia Sabater; Alex Iranzo; Joan Santamaria Cano; Josep Dalmau; Francesc Graus Journal: Neurology Date: 2021-08-11 Impact factor: 11.800
Authors: Maria Elena Erro; Lidia Sabater; Laura Martínez; María Herrera; Aiora Ostolaza; Iñaki García de Gurtubay; Teresa Tuñón; Francesc Graus; Ellen Gelpi Journal: Neurol Neuroimmunol Neuroinflamm Date: 2019-12-11